HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND)...
Hence then, the article about geneditbio receives fda clearance of ind application for its lead in vivo genome editing program geb 101 for tgfbi corneal dystrophy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy )
Also on site :
- Maduro Could Have Avoided His Capture Entirely if He Had Checked This App
- ‘He broke’: 93-year-old Fremont man told police he spent month planning to kill wife, docs say
- Man dies after stabbing in Denver’s Sunnyside neighborhood